



## JAGSONPAL PHARMACEUTICALS LIMITED

CIN: L74899DL1978PLC009181

Registered Office: T-210 J, Shahpur Jat, New Delhi – 110049

Phone: 011-46181100 & 46109900, FAX: 011-26498341

Website: [www.jagsonpal.com](http://www.jagsonpal.com) , E-mail: [nandita.singh@jagsonpal.com](mailto:nandita.singh@jagsonpal.com)

Date: April 26 <sup>th</sup> , 2022	
The Manager Listing Agreement The National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051.	The Manager Listing Agreement The BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001.
<b>CM Quote : JAGSNPHARM</b>	<b>SCRIP Code : 507789</b>
<b>Subject: Submission of Certificate under Sub- Regulation 9 &amp; 10 Regulation 40 of the SEBI (Listing Obligations &amp; Disclosure Requirement) Regulations, 2015 for the year ended 31<sup>st</sup> March, 2022.</b>	

Dear Sir & Madam,

Pursuant to the provisions of Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations' "), please find enclosed herewith the Certificate dated April 22, 2022 for the year ended March 31<sup>st</sup>, 2022. This certificate has been issued by Mr. Mukesh Arora, Proprietor of M/s Mukesh Arora & Co.

You are requested to take the above information on record.

You are requested to do the needful.

For JAGSONPAL PHARMACEUTICALS LIMITED

  
  
Nandita Singh  
Company Secretary & Compliance Officer  
Membership No.: A48520

**Factory: 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone: 0091-95129-2275952, 2275953**



**CERTIFICATE UNDER REGULATION 40(9) OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

**FOR THE YEAR ENDED ON 31<sup>ST</sup> MARCH, 2022.**

I have examined all share transfer deeds, memorandum of transfers, sub-division, consolidation, renewal, exchange or endorsement of calls/ allotment monies, registers, files and other documents relating to **JAGSON PAL PHARMACEUTICALS LIMITED** maintained by **MCS SHARE TRANSFER AGENT LIMITED** pertaining to transfer of equity shares of the company for the period from 1<sup>ST</sup> April, 2021 to 31<sup>ST</sup> March, 2022 for the purpose of issuing a certificate as per regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 entered into by, **JAGSON PAL PHARMACEUTICALS LIMITED** with **BSE LTD and NSE LTD** and based on the information provided by the company, I hereby certify that:

- a) There was no occasion to deliver any share certificate after transfer during the year ended on 31<sup>ST</sup> March, 2022 as no request for transfer of shares was received during the period from 1st April, 2021 to 31<sup>ST</sup> March, 2022.
- b) Share Certificates relating to the Duplicate shares received during the period from 1<sup>ST</sup> April, 2021 to 31<sup>ST</sup> March, 2022 have been issued within thirty days of the date of lodgement.
- c) There was no case of sub-division, consolidation, renewal, exchange or endorsement of calls/allotment monies from respective date of lodgement of each deed within this period.

**Place: New Delhi**

**Date: 22.04.2022**

**UDIN: F004819D000189355**

**FOR MUKESH ARORA & CO.  
COMPANY SECRETARY**

**(MUKESH ARORA – PROP.)**

**F.C.S. 4819**

**C.P. 4405**

